Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are taking his smiles and chuckles to mean what you want them to mean, that there are AMBS material events that Gerald knows about but just can't state publicly. Possible, I agree.
What we do know about AMBS is that they are under a NDA with a major research institute in California.
Why ? Can't you talk about it ?
Crystal Balls.
Just call me Juan Valdez.
NEWC is diversifying big time
Big News
MANF Diabetes Research Program
http://www.evaluategroup.com/Universal/View.aspx?type=Search&query=MANF
AMBS has all the patents to MANF
who is logging into this site?
Concurrently with this announcement, Amarantus announced that it has executed an Exclusive Option Agreement with the University of Massachusetts Medical School ("UMMS") to license intellectual property recently developed at UMMS to advance Amarantus' diabetes diagnostic development and commercialization program using Amarantus' lead protein MANF as a biomarker for beta cell stress
Johnston Associates Inc were also mentioned as part of the latest AMBS investor group... they seem to have a nice track record in Biotech & have experience with Diagnostics & therapeutics that involve AD , PD and mis-folding proteins
http://www.jaivc.com/
http://www.jaivc.com/portfolio.html
JV contingent - smart move by BD but it will also probably cost them more now than back then when they signed that agreement.
"quote me again"
original thinker
thanks for the quote.. saved me a click
"BD" thats original ..
Go Lions
you are making fun of his grammar, I am making fun of your unoriginality
but thanks for saving posters from the dreaded having to remember what they just posted.. or having to click on the link to the previous post.. life saver.
Gerald's communication to shareholders is far greater than most other stocks i have had contact with. I really don't mind.
Go Lions
Almost every one of his paragraphs begins with "and so..."
major research institute in California can't speak who they are because we're under NDA.
As I said before we are undergoing a strategic review and what's really driving is the first data set that we've received now from two independent groups one in Miami and another at the major research institute in California can't speak who they are because we're under NDA. -
Retinitis Pigmentosa is an Orphan Disease Indication , the proper terminology is that AMBS will apply for Orphan Designation for MANF as a treatment for RP.
GL2ALL
Russel Miller , Randal grimes
Page 8. :)
Thats page 8. You need to read more carefully. Funds have been raised. They even added a new employee. Maybe more as i type this. Again what issue , Next?
Stick to the 2015 AMBS funding angle. 2014 is covered.
Your predictions are pretty spot on.
Nice way of covering all angles. Now if JV. If Grants. Nice.
What issue? You mean Where they state they needed to raise funds to meet next milestone and operate and now did? Issue resolved.
He just did finance AMBS
Not so bogus, is it now?
Your AMBS posting has increased? What gives ? what are you worried about?
You gave up on the 2014 funding. Now you need to step it up to 2015?
That other test is limited to Abeta detection.. AMBS LymPro is centered on Tau Protein ...
More recent hypotheses center on the effects of the misfolded and aggregated proteins, amyloid beta and tau. The two positions are lightheartedly described as "ba-ptist" and "tau-ist" viewpoints in one scientific publication. Therein, it is suggested that "Tau-ists" believe that the tau protein abnormalities initiate the disease cascade, while "ba-ptists" believe that beta amyloid deposits are the causative factor in the disease.[18]
Cell cycle dysfunction has been hypothesized to be a hallmark of AD since the late 1990's, although little was known about how it related to Alzheimer's markers such as Amyloid-beta and Tau. Recent evidence suggests that the link between cell cycle dysfunction, Amyloid-beta and Tau is centered around the mammalian target of rapamycin (mTOR), which mediates a number of biological processes including cell cycle re-entry. Recent peer-reviewed literature (jcs.biologists.org/content/126/5/1278.short) has identified the link between Amyloid-beta and Tau degradation via cell-cycle dysfunction in AD. As a result of this new information, a clear link has been established between Amyloid-beta, Tau and LymPro which further validates the scientific principles underpinning the assay, thereby increasing its scientific validity as a potentially vital diagnostic blood test for AD.
Wow you are really hurting to get back into AMBS. Lol. good luck.
Excellent Entry price for an upstart and promising - resource company.
Last ditch effort to shake the weak hands and Cover. They know what is coming For AMBS. They are paranoid news will drop sooner. Maybe even tomorrow.
GL2ALL
from AMBS PR "Recent peer-reviewed literature (http://jcs.biologists.org/content/126/5/1278.short) has identified the link between Amyloid-beta and Tau degradation via cell-cycle dysfunction in AD. As a result of this new information, a clear link has been established between Amyloid-beta, Tau and LymPro which further validates the scientific principles underpinning the assay, thereby increasing its scientific validity as a potentially vital diagnostic blood test for AD."
LymPro Validation getting near.
AMBS
GL2ALL
Concurrently with this announcement, Amarantus announced that it has executed an Exclusive Option Agreement with the University of Massachusetts Medical School ("UMMS") to license intellectual property recently developed at UMMS to advance Amarantus' diabetes diagnostic development and commercialization program using Amarantus' lead protein MANF as a biomarker for beta cell stress.
http://markets.financialcontent.com/stocks/news/read/18673668/Generex_Biotechnology_and_Amarantus_BioSciences_Announce_Oral
"I am delighted to join Amarantus at a time when the Company is preparing for the introduction of this highly specific and sensitive diagnostic assay for Alzheimer's disease into the marketplace. Market launch of diagnostic products requires significant strategy in regards to initial commercial sales, regulatory matters, reimbursement and other important considerations. I am looking forward to helping the team at Amarantus make value-building decisions for both the short-term and long-term success of LymPro commercial launch and ultimate regulatory approval for widespread use."
This has been Verified already... and the Validation announcement is next PR....
http://ir.stockpr.com/amarantus/company-news/detail/854/amarantus-appoints-dr-colin-bier-to-advisory-board-for-lympro-commercialization
Report TOS
AMBS will file PreSubmission App to FDA for LymPro in 3rd Quarter 2013
GL2ALL
MANF Diabetes Research Program
http://www.evaluategroup.com/Universal/View.aspx?type=Search&query=MANF
AMBS has all the patents to MANF
market intel ....i wonder who is logging into this site?
Big news on the way.
$$$$$$$$ NEWC
You left out how AMBS also attracts a Highly reputable Board of Advisors each with a Resume that rivals any Big Pharma..
the Untypical part that trumps and proves wrong any of your Typical assumption...
From my research the answer is no. And by diagnosing 8 years before signs of cancerous cells. This is what sets it apart from the rest.
GL
I did not say you could move AMBS pps. I am just guessing your intentions. And i wished you luck.
I see you sold and now looking for lower AMBS entry. gl2U
You left out how AMBS also attracts a Highly reputable Board of Advisors each with a Resume that rivals any Big Pharma..
the Untypical part that trumps and proves wrong any of your Typical assumption...
AMBS will file PreSubmission App to FDA for LymPro in 3rd Quarter 2013 this was also noted in the original LymPro White Paper
GL2ALL
This comes into play also IMO From 2011- Amarantus announced that it has executed an Exclusive Option Agreement with the University of Massachusetts Medical School ("UMMS") to license intellectual property recently developed at UMMS to advance Amarantus' diabetes diagnostic development and commercialization program using Amarantus' lead protein MANF as a biomarker for beta cell stress.
"The joint efforts of many players, starting from the discovery of a new use of MANF at UMass Medical School for diabetes, and the synergies of two highly committed organizations, has allowed us to generate a unique opportunity to launch a commercial development program for MANF as a biomarker of cellular stress and stressed beta cells in diabetes," said Dr. Fumihiko Urano, associate professor at the University of Massachusetts Medical School, who identified MANF's role in this area.
http://markets.financialcontent.com/stocks/news/read/18673668/Generex_Biotechnology_and_Amarantus_BioSciences_Announce_Oral
"I am delighted to join Amarantus at a time when the Company is preparing for the introduction of this highly specific and sensitive diagnostic assay for Alzheimer's disease into the marketplace. Market launch of diagnostic products requires significant strategy in regards to initial commercial sales, regulatory matters, reimbursement and other important considerations. I am looking forward to helping the team at Amarantus make value-building decisions for both the short-term and long-term success of LymPro commercial launch and ultimate regulatory approval for widespread use."
This has been Verified already... and the Validation announcement is next PR....
http://ir.stockpr.com/amarantus/company-news/detail/854/amarantus-appoints-dr-colin-bier-to-advisory-board-for-lympro-commercialization
If and when they are positive. AMBS will have money to spare, that statement of yours has very little logical thought behind it
Dr Simon, world recognized expert in AD biomarkers disagrees. Good for Amarantus he is on their Board of Advisors.
nice summary, also you may be able to add in the LymPro section
File PRE-Submission App to FDA for LymPro 3rd Quarter 2013 it was in the original AMBS LymPro White Paper. Chart on page 21
this may change but it was on the Chart.
GL
No TKO Yet , NDA can be for Type 1 Diabetes Orphan Ind with licensing of MANF involved.
AMBS has IP options for MANF in Diabetes
All will be revealed soon.
GL2ALL